Piper Sandler Reiterates Overweight on Tandem Diabetes Care, Raises Price Target to $50
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Matt O'Brien has reiterated an Overweight rating on Tandem Diabetes Care (NASDAQ:TNDM) and increased the price target from $35 to $50.

May 03, 2024 | 1:17 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler has reiterated an Overweight rating on Tandem Diabetes Care and raised the price target from $35 to $50.
The reiteration of an Overweight rating combined with a significant increase in the price target from $35 to $50 by a reputable analyst firm like Piper Sandler is a strong positive signal for TNDM. This adjustment reflects a bullish outlook on the company's future performance and is likely to influence investor sentiment positively, potentially leading to a short-term increase in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100